TCR2 Therapeutics

$27.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.25 (-0.90%) Today

$0.00 (0.00%) As of 10:00 PM UTC after-hours

Why Robinhood?

You can buy or sell TCRR and other stocks, options, and ETFs commission-free!

About TCRR

TCR2 Therapeutics Inc. Common Stock, also called TCR2 Therapeutics, is an immunotherapy company, which develops biological drugs and engineering t-cells for cancer therapy. The firm offers cancer therapy, t-cell biology, immunology and molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of t-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle in May 2015 and is headquartered in Cambridge, MA. The listed name for TCRR is TCR2 Therapeutics Inc. Common Stock.

CEO

Garry E. Menzel

Employees

Headquarters

Cambridge, Massachusetts

Founded

2015

Market Cap

919.11M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

387.05K

High Today

$28.32

Low Today

$27.30

Open Price

$27.89

Volume

169.73K

52 Week High

$30.00

52 Week Low

$5.84

Collections

Analyst Ratings

100%

of 9 ratings

Buy

100%

Hold

Sell

TCRR Earnings

-$4.85

-$3.23

-$1.62

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 30, Pre-Market